The increased expression of VEGF family in tumours has been associated with poor prognosis or increased risk of recurrence or metastasis in several types of cancers [16] and, currently, several pro- or anti-angiogenic drugs have been approved by the FDA or are in clinical trials [17]. The gene discussed is VEGFA; the disease is cancer.